Advertisement
U.S. markets closed

AVROBIO, Inc. (AVRO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.2800+0.0200 (+1.59%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close1.2600
Open1.2500
Bid1.2600 x 100
Ask1.3000 x 100
Day's Range1.2500 - 1.3000
52 Week Range0.5700 - 1.7000
Volume104,197
Avg. Volume317,411
Market Cap57.421M
Beta (5Y Monthly)1.23
PE Ratio (TTM)4.74
EPS (TTM)0.2700
Earnings DateMay 09, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AVRO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • AVROBIO, Inc.
    Daily – Vickers Top Buyers & Sellers for 07/09/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    3 years agoArgus Research
View more
  • BioPharma Dive

    Avrobio’s road ends in reverse merger with Tim Springer-backed startup

    The gene therapy developer’s demise has given Tectonic Therapeutic, a GPCR-focused startup founded by the prolific biotech entrepreneur, an alternate path to the public markets.

  • Business Wire

    AVROBIO and Tectonic Therapeutic Announce Merger

    CAMBRIDGE, Mass. & WATERTOWN, Mass., January 30, 2024--AVROBIO, Inc. (Nasdaq: AVRO) and Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that the companies have entered into a definitive merger agreement to combine in an all-stock transaction (the "Merger"). Under the terms of the agreement, AVR

  • Zacks

    Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?

    Here is how AVROBIO, Inc. (AVRO) and Crinetics Pharmaceuticals, Inc. (CRNX) have performed compared to their sector so far this year.